Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Antiviral drugs, such as nelfinavir mesylate, may help prevent cancer cells from
spreading.
PURPOSE: This phase I/II trial is studying the side effects and best dose of nelfinavir
mesylate and to see how well it works in treating patients with recurrent, metastatic, or
unresectable liposarcoma.